Dicerna Pharmaceuticals Logo

Email this page: News Release

Dicerna Expands Lead GalXC™ Development Program to Encompass All Forms of Primary Hyperoxaluria (PH) and Reveals New Therapeutic Target for DCR-PHXC

For security reasons, registration is required before you can use this feature.
* Indicates required field